Safety Monitoring of Medicinal Products: Guidelines for Setting Up and Running a Pharmacovigilance Centre
(2000; 28 pages) [French]
Table of Contents
View the documentINTRODUCTION
View the document1. WHY PHARMACOVIGILANCE?
View the document2. DEFINITION AND AIMS
Open this folder and view contents3. HOW TO START A PHARMACOVIGILANCE CENTRE
Open this folder and view contents4. REPORTING OF ADVERSE DRUG REACTIONS
Open this folder and view contents5. SPECIAL ISSUES IN REPORTING
Open this folder and view contents6. PRACTICALITIES IN THE ORGANISATION OF A PHARMACOVIGILANCE CENTRE
Open this folder and view contents7. ASSESSMENT OF CASE REPORTS
Close this folder8. USE OF THE DATA
View the document8.1 Hypothesis generation and strengthening
View the document8.2 Drug regulation
View the document8.3 Information
View the document8.4 Education and feedback
View the document8.5 Limitations regarding the use of the data
Open this folder and view contents9. RELATIONS WITH OTHER PARTIES
View the document10. OTHER SOURCES OF INFORMATION
View the document11. FUNDING
View the documentREFERENCES
View the documentGLOSSARY
View the documentCAUSALITY CATEGORIES
View the documentWHO CONTACTS
 

8.3 Information

For the dissemination of information of current importance or interest to healthcare practitioners, an adverse drug reactions bulletin or a column in medical and pharmaceutical journals may be very helpful. In the case of an emergency, a letter directly to all doctors and pharmacists may be needed. Usually such actions take place in collaboration with the regulatory authority and the pharmaceutical company’s experts.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 6, 2017